CA2500531A1 - Method for treating or preventing metastasis of colorectal cancers - Google Patents
Method for treating or preventing metastasis of colorectal cancers Download PDFInfo
- Publication number
- CA2500531A1 CA2500531A1 CA002500531A CA2500531A CA2500531A1 CA 2500531 A1 CA2500531 A1 CA 2500531A1 CA 002500531 A CA002500531 A CA 002500531A CA 2500531 A CA2500531 A CA 2500531A CA 2500531 A1 CA2500531 A1 CA 2500531A1
- Authority
- CA
- Canada
- Prior art keywords
- polypeptide
- colorectal cancer
- group
- mlxs
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41470902P | 2002-09-30 | 2002-09-30 | |
| US60/414,709 | 2002-09-30 | ||
| PCT/JP2003/010338 WO2004031774A2 (en) | 2002-09-30 | 2003-08-14 | Method for treating or preventing metastasis of colorectal cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2500531A1 true CA2500531A1 (en) | 2004-04-15 |
Family
ID=32069759
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002500531A Abandoned CA2500531A1 (en) | 2002-09-30 | 2003-08-14 | Method for treating or preventing metastasis of colorectal cancers |
| CA002500538A Abandoned CA2500538A1 (en) | 2002-09-30 | 2003-08-14 | Method for treating or preventing metastasis of colorectal cancers |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002500538A Abandoned CA2500538A1 (en) | 2002-09-30 | 2003-08-14 | Method for treating or preventing metastasis of colorectal cancers |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20060210576A1 (2) |
| EP (2) | EP1546730A2 (2) |
| JP (2) | JP2006500945A (2) |
| AU (2) | AU2003257849A1 (2) |
| CA (2) | CA2500531A1 (2) |
| WO (2) | WO2004031774A2 (2) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060240425A1 (en) * | 2002-09-30 | 2006-10-26 | Oncotherapy Science, Inc | Genes and polypeptides relating to myeloid leukemia |
| WO2007026355A2 (en) * | 2005-08-29 | 2007-03-08 | Yeda Research And Development Co. Ltd. | Modulators of cell migration and methods of identifying same |
| EP2180320A1 (en) * | 2006-06-05 | 2010-04-28 | Shimadzu Corporation | Tumor marker and method for determination of the occurence of cancerous disease |
| DE102006035393A1 (de) * | 2006-11-02 | 2008-05-15 | Signature Diagnostics Ag | Prognostische Marker für die Klassifizierung des dreijährigen progessionsfreien Überlebens von Patienten mit Kolonkarzinomen basierend auf Expressionsprofilen von biologischen Proben |
| AU2008206515A1 (en) * | 2007-01-11 | 2008-07-24 | Genentech, Inc. | Genetic variations associated with tumors |
| JP5548872B2 (ja) * | 2010-08-26 | 2014-07-16 | 株式会社島津製作所 | 大腸がん肝転移マーカー、及び試料中の大腸がん肝転移マーカーの分析方法 |
| US20200391053A1 (en) * | 2019-06-13 | 2020-12-17 | Canon Medical Systems Corporation | Radiotherapy system, therapy planning support method, and therapy planning method |
| CN115490758A (zh) * | 2021-06-17 | 2022-12-20 | 温州医科大学 | 一种用于治疗或辅助治疗结直肠癌的抗肿瘤多肽ccr313及其应用 |
| CN117801060A (zh) * | 2022-09-26 | 2024-04-02 | 深圳碳云智肽药物科技有限公司 | 一种抗肿瘤多肽及应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030077568A1 (en) * | 2000-09-15 | 2003-04-24 | Gish Kurt C. | Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators |
| US20040009489A1 (en) * | 2001-09-28 | 2004-01-15 | Golub Todd R. | Classification of lung carcinomas using gene expression analysis |
-
2003
- 2003-08-14 JP JP2004541213A patent/JP2006500945A/ja not_active Withdrawn
- 2003-08-14 AU AU2003257849A patent/AU2003257849A1/en not_active Abandoned
- 2003-08-14 JP JP2004541214A patent/JP2006501465A/ja not_active Withdrawn
- 2003-08-14 CA CA002500531A patent/CA2500531A1/en not_active Abandoned
- 2003-08-14 WO PCT/JP2003/010338 patent/WO2004031774A2/en not_active Ceased
- 2003-08-14 EP EP03799081A patent/EP1546730A2/en not_active Withdrawn
- 2003-08-14 US US10/529,694 patent/US20060210576A1/en not_active Abandoned
- 2003-08-14 CA CA002500538A patent/CA2500538A1/en not_active Abandoned
- 2003-08-14 WO PCT/JP2003/010339 patent/WO2004031775A2/en not_active Ceased
- 2003-08-14 EP EP03799082A patent/EP1546731A2/en not_active Withdrawn
- 2003-08-14 AU AU2003256075A patent/AU2003256075A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006501465A (ja) | 2006-01-12 |
| AU2003257849A1 (en) | 2004-04-23 |
| AU2003256075A8 (en) | 2004-04-23 |
| WO2004031775A3 (en) | 2004-10-14 |
| EP1546731A2 (en) | 2005-06-29 |
| WO2004031774A3 (en) | 2004-10-14 |
| WO2004031774A2 (en) | 2004-04-15 |
| US20060210576A1 (en) | 2006-09-21 |
| AU2003256075A1 (en) | 2004-04-23 |
| EP1546730A2 (en) | 2005-06-29 |
| WO2004031775A2 (en) | 2004-04-15 |
| AU2003257849A8 (en) | 2004-04-23 |
| CA2500538A1 (en) | 2004-04-15 |
| JP2006500945A (ja) | 2006-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1556518B1 (en) | Genes and polypeptides relating to human pancreatic cancers | |
| US20050259483A1 (en) | Genes and polypeptides relating to prostate cancers | |
| WO2006085684A9 (en) | Method of diagnosing bladder cancer | |
| EP1668354A2 (en) | Method of diagnosing breast cancer | |
| CA2500405A1 (en) | Genes and polypeptides relating to human myeloid leukemia | |
| WO2004031413A2 (en) | Method for diagnosing non-small cell lung cancers | |
| US7521205B2 (en) | Genes and polypeptides relating to prostate cancers | |
| US20060281081A1 (en) | Method of diagnosing colon and gastric cancers | |
| CA2500531A1 (en) | Method for treating or preventing metastasis of colorectal cancers | |
| US20070202109A1 (en) | Method Of Diagnosing Breast Cancer | |
| US20060111314A1 (en) | Method for treating or preventing metastasis of colorectal cancers | |
| US8067153B2 (en) | Genes and polypeptides relating to prostate cancers | |
| US20060240425A1 (en) | Genes and polypeptides relating to myeloid leukemia | |
| WO2005090398A1 (en) | Genes and polypeptides relating to prostate cancers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |